<< CSR 1975-2010 Home

The navigation below allows you to jump to any table or figure within the SEER Cancer Statistics Review.

  1. First select the CSR Section, then a Table/Figure from that section.
  2. Use the Submit button to view the table or figure. You will have options to download a printer-friendly version or the data table (CSV) as well.

To learn more about the Cancer Statistics Review and the statistics presented in this report, refer to the About the CSR (PDF, 85 KB) and Technical Notes (PDF, 282 KB) pages.


Download and Print: Download Printer-friendly PDF Download data

Table 1.22

U.S. Prevalence Counts, Invasive Cancers Only, January 1, 2010a Using Different Tumor Inclusion Criteriab
Site Sex 5-Year Limited Duration Prevalence 35-year Limited Duration Prevalence
1st Invasive
Tumor Everc		 1st Per Site in
Previous 35 Yearsd		 1st Per Site in
Previous 5 Yearse		 1st Invasive
Tumor Everc		 1st Per Site in
Previous 35 Yearsd
All Sites Both Sexes 4,511,266 4,598,344 5,044,168 12,600,627 12,810,577
Male 2,332,050 2,366,640 2,584,260 5,990,343 6,060,178
Female 2,179,216 2,231,704 2,459,908 6,610,284 6,750,399
Oral Cavity & Pharynx Both Sexes 102,019 117,112 121,258 264,620 291,343
Male 71,123 80,929 83,544 175,045 190,951
Female 30,896 36,183 37,714 89,575 100,392
Esophagus Both Sexes 21,268 25,973 26,092 33,702 39,594
Male 16,808 20,399 20,447 26,317 30,715
Female 4,460 5,574 5,645 7,385 8,879
Stomach Both Sexes 35,420 42,280 42,609 70,821 81,142
Male 21,286 25,765 25,901 40,560 46,844
Female 14,134 16,515 16,708 30,261 34,298
Colon & Rectum Both Sexes 407,833 471,251 480,046 1,129,666 1,258,620
Male 207,302 239,824 244,132 561,245 622,211
Female 200,531 231,427 235,914 568,421 636,409
Liver & Intrahepatic Bile Duct Both Sexes 30,577 34,834 34,867 40,940 45,832
Male 22,266 25,232 25,265 28,891 32,221
Female 8,311 9,602 9,602 12,049 13,611
Pancreas Both Sexes 31,442 38,275 38,275 41,284 49,174
Male 15,733 19,467 19,467 20,155 24,367
Female 15,709 18,808 18,808 21,129 24,807
Larynx Both Sexes 30,947 37,152 37,518 87,135 98,063
Male 25,107 30,036 30,356 70,117 78,586
Female 5,840 7,116 7,162 17,018 19,477
Lung & Bronchus Both Sexes 231,996 296,283 304,764 391,564 480,133
Male 108,211 140,119 143,487 178,912 220,472
Female 123,785 156,164 161,277 212,652 259,661
Melanoma of the Skin Both Sexes 276,312 312,334 325,566 884,259 953,581
Male 148,749 171,783 180,200 440,298 480,917
Female 127,563 140,551 145,366 443,961 472,664
Breast Female 842,193 909,424 965,835 2,770,060 2,934,536
Cervix Female 38,963 40,783 40,907 208,065 213,819
Corpus & Uterus, NOS Female 169,126 189,983 190,106 569,448 620,803
Ovaryf Female 57,207 66,063 66,139 169,398 190,511
Prostate Male 1,026,391 1,107,903 1,107,977 2,616,190 2,787,286
Testis Male 42,302 43,012 43,616 205,130 207,844
Urinary Bladder Both Sexes 198,998 248,244 253,143 551,278 641,106
Male 151,489 190,075 194,009 411,638 479,012
Female 47,509 58,169 59,134 139,640 162,094
Kidney & Renal Pelvis Both Sexes 145,766 177,066 179,051 330,450 385,370
Male 88,557 108,930 110,317 196,335 230,734
Female 57,209 68,136 68,734 134,115 154,636
Brain & Nervous System Both Sexes 43,995 46,883 47,345 128,063 132,164
Male 24,044 25,790 26,033 68,158 70,466
Female 19,951 21,093 21,312 59,905 61,698
Thyroid Both Sexes 165,253 183,524 184,093 494,969 528,131
Male 37,076 42,905 43,058 107,747 117,569
Female 128,177 140,619 141,035 387,222 410,562
Hodgkin Lymphoma Both Sexes 39,048 41,589 41,611 168,309 172,937
Male 21,122 22,557 22,568 87,084 89,522
Female 17,926 19,032 19,043 81,225 83,415
Non-Hodgkin Lymphoma Both Sexes 198,946 233,585 235,457 499,712 558,340
Male 105,553 125,451 126,442 261,560 292,961
Female 93,393 108,134 109,015 238,152 265,379
Myeloma Both Sexes 49,451 58,292 58,328 77,360 88,490
Male 26,622 32,063 32,087 42,092 48,802
Female 22,829 26,229 26,241 35,268 39,688
Leukemia Both Sexes 112,120 129,298 129,528 282,150 310,046
Male 64,915 75,612 75,711 160,039 176,801
Female 47,205 53,686 53,817 122,111 133,245
Acute Lymphocytic Leukemia Both Sexes 16,205 16,686 16,686 66,030 66,759
Male 9,215 9,443 9,443 36,418 36,708
Female 6,990 7,243 7,243 29,612 30,051
Childhood (Ages 0-19) Both Sexes 63,904 63,977 64,503 304,247 304,716
Male 33,948 33,981 34,250 156,819 157,032
Female 29,956 29,996 30,253 147,428 147,684
Kaposi Sarcoma Both Sexes 7,319 7,750 7,750 24,815 25,977
Male 6,865 7,208 7,208 23,533 24,518
Female 454 542 542 1,282 1,459
Mesothelioma Both Sexes 2,968 3,926 3,938 4,538 5,658
Male 1,998 2,761 2,773 2,601 3,467
Female 970 1,165 1,165 1,937 2,191

Footnotes:

a U.S. 2010 cancer prevalence counts are based on 2010 cancer prevalence proportions from the SEER 9 registries and 1/1/2010 U.S. population estimates based on the average of 2009 and 2010 population estimates from the U.S. Bureau of the Census.

b Prevalence estimates are ambiguous for those with multiple cancers, unless the tumor inclusion criteria are understood. Depending on the application, different inclusion criteria may be appropriate. This table provides three different methods of tumor inclusion which are listed in footnotes (c) to (e).

c First invasive tumor ever. Referred to as method (c) in Example below.

d First invasive tumor for each cancer site diagnosed during the previous 35 years (1975-2009). All sites is treated as a separate cancer "site". Referred to as method (d) in Example below.

e First invasive tumor for each cancer site diagnosed during the previous 5 years (2005-2009). All sites is treated as a separate cancer "site". Referred to as method (e) in Example below.

Example: Consider a woman who had three invasive cancers: Melanoma in 1981; Breast cancer in 2005; Melanoma in 2006.
In method (c) the melanoma is the woman's first cancer, and is counted for the melanoma and all sites 35-year limited duration prevalence. For 5-year limited duration prevalence, the woman is not counted at all since her first cancer occurred more than 5 years prior to 1/1/2010.
In method (d) the 1981 melanoma is counted for the melanoma and all sites 35-year limited duration prevalence. The 2005 breast cancer is counted for the breast 5-year and 35-year limited duration prevalence.
In method (e) the 2005 breast cancer is counted for the breast cancer and all sites 5-year limited duration prevalence. The 2006 melanoma is counted for 5-year limited duration prevalence for melanoma.

f Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

Page Navigation: << Previous Next >>

The information on this page is archived and provided for reference purposes only. Persons with disabilities having difficulty accessing information on this page may e-mail for assistance.